Vetenskapliga artiklar

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02243-1/fulltext

Kampf, G., (2021-11-20), The Lancet, COVID-19: stigmatising the unvaccinated is not justified. Enligt Kampf, sprider injicerade smitta lika bra som icke injicerade. Det är därför både felaktigt och farligt att prata om en pandemi av ”ovaccinerade” och ger även flera exempel på att det både är fler ”vaccinerade” som smittas och att andelen symptomfria bland smittbärande, är lika hög bland ”vaccinerade” som ”ovaccinerade”, liksom att bevisen för detta, hela tiden ökar. Exemplen han anger, indikerar dessutom att den symptomfria smittspridningen till och med är högre bland ”vaccinerade”.

https://www.researchsquare.com/article/rs-1121993/v1

Killingley, B., Mann, A., Kalinova, M., Boyers, A., Goonawardane, N., Zhou, J., Lindsell, K., Hare, S. S., Brown, J., Frise, R., Smith, E., Hopkins, C., Noulin, N., Londt, B., Wilkinson, T., Harden, S., McShane, H., Baillet, M., Gilbert, A., Jacobs, M., Charman, C., Mande, P., Nguyen-Van-Tam, J. S., Semple, M. G., Read, R. C., Ferguson, N. M., Openshaw, P. J., Rapeport, G., Barclay, W. S., Catchpole, A. P., Chiu, C., (2022-02-01), Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge. ”To establish a novel SARS-CoV-2 human challenge model, 36 volunteers aged 18-29 years without evidence of previous infection or vaccination were inoculated with 10 TCID50 of a wild-type virus (SARS- CoV-2/human/GBR/484861/2020) intranasally. Two participants were excluded from per protocol analysis due to seroconversion between screening and inoculation. Eighteen (~53%) became infected, with viral load (VL) rising steeply and peaking at ~5 days post-inoculation. Virus was hroat but rose to signis even in asymptomatic infection, followed by the development of serum spike-specihown. ClinicalTrials.gov identi

https://www.researchgate.net/publication/356756711_Latest_statistics_on_England_mortality_data_suggest_systematic_mis-categorisation_of_vaccine_status_and_uncertain_effectiveness_of_Covid-19_vaccination

Neil, M., Fenton, N. E., Smalley, J., Craig, C., Guetzkow, J., Mclachlan, S., Engler, J., Rose, J., (2021-12-03), Latest statistics on England mortality data suggest systematic mis-categorisation of vaccine status and uncertain effectiveness of Covid-19 vaccination. Det är inte bara danskarnas SSI – den danska motsvarigheten till Folkhälsomyndigheten som har ”boostat” statistiken. Enligt en ny studie, har även flera myndigheter i Storbritannien fifflat med siffrorna för att ”boosta” sin statistik. Fynden gör att vaccinens påstådda effektivitet ifrågasätts. Myndigheternas statistik beskrivs som opålitlig och missvisande.  

https://www.pnas.org/content/119/6/e2112663119

Ringlander, J., Fingal, J., Kann, H., Prakash, K., Rydell, G., Andersson, M., Martner, A., Lindh, M., Horal, P., Hellstrand, K., Kann, M., (2022-02-08), Impact of ADAR-induced editing of minor viral RNA populations on replication and transmission of SARS-CoV-2. ”Adenosine deaminases acting on RNA (ADAR) are RNA-editing enzymes that may restrict viral infection. We have utilized deep sequencing to determine adenosine to guanine (A→G) mutations, signifying ADAR activity, in clinical samples retrieved from 93 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–infected patients in the early phase of the COVID-19 pandemic. A→G mutations were detected in 0.035% (median) of RNA residues and were predominantly nonsynonymous. These mutations were rarely detected in the major viral population but were abundant in minor viral populations in which A→G was more prevalent than any other mutation (P < 0.001). The A→G substitutions accumulated in the spike protein gene at positions corresponding to amino acids 505 to 510 in the receptor binding motif and at amino acids 650 to 655. The frequency of A→G mutations in minor viral populations was significantly associated with low viral load (P < 0.001). We additionally analyzed A→G mutations in 288,247 SARS-CoV-2 major (consensus) sequences representing the dominant viral population. The A→G mutations observed in minor viral populations in the initial patient cohort were increasingly detected in European consensus sequences between March and June 2020 (P < 0.001) followed by a decline of these mutations in autumn and early winter (P < 0.001). We propose that ADAR-induced deamination of RNA is a significant source of mutated SARS-CoV-2 and hypothesize that the degree of RNA deamination may determine or reflect viral fitness and infectivity.”

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690270/

Yu, W., Rohli, K. E., Yang, S., Jiad, P., (2020-11-26), Impact of obesity on COVID-19 patients. ”The COVID-19 pandemic is characterized by a high incidence of severe and acute organ damage, especially the lungs with SARS, but also acute cardiovascular events, in association with a pro-inflammatory cytokine-related storm.104 Such severe acute events are particularly prevalent among aged individuals and patients with co-morbidities such as obesity, hypertension, and Type 2 diabetes which have emerged as major contributors to the severity of symptoms and organ failure, whilst the current studies report a lower prevalence of severe COVID-19 infection among smokers and people with chronic lung diseases. These observations suggest the importance of the “metabolic disease exposome”,105 including dietary lifestyle, glycaemic disorders, obesity, and sedentariness, among other potential disease severity modifiers, such as systemic hypertension and aging, leading to chronic low-grade inflammation, which may aggravate COVID-19-induced acute organ failure.”

https://www.medrxiv.org/content/10.1101/2022.01.05.22268782v1

Altarawneh, H., Chemaitelly, H., Tang, P., Hasan, M. R., Qassim, S., Ayoub, H. H., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Al Kanaani, Z., Al Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K.,Al Kuwari, M. G., Butt, A. A., Al Romaihi, H. E., Al-Thani, M. H., Al Khal, A., Bertollini, R., Abu-Raddad, L. J., (2022-01-06), Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. ”BACKGROUND Natural SARS-CoV-2 infection elicits strong protection against reinfection with the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. However, the Omicron (B.1.1.529) variant harbors multiple mutations that can mediate immune evasion. We estimated effectiveness of prior infection in preventing reinfection (PES) with Omicron and other SARS-CoV-2 variants in Qatar. METHODS PES was estimated using the test-negative, case-control study design, employing a methodology that was recently investigated and validated for derivation of robust estimates for PES. Cases (PCR-positive persons with a variant infection) and controls (PCR-negative persons) were exact-matched by sex, 10-year age group, nationality, and calendar time of PCR test, to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar. RESULTS PES against symptomatic reinfection was estimated at 90.2% (95% CI: 60.2-97.6) for Alpha, 84.8% (95% CI: 74.5-91.0) for Beta, 92.0% (95% CI: 87.9-94.7) for Delta, and 56.0% (95% CI: 50.6-60.9) for Omicron. Only 1 Alpha, 2 Beta, 0 Delta, and 2 Omicron reinfections progressed to severe COVID-19. None progressed to critical or fatal COVID-19. PES against hospitalization or death due to reinfection was estimated at 69.4% (95% CI: −143.6-96.2) for Alpha, 88.0% (95% CI: 50.7-97.1) for Beta, 100% (95% CI: 43.3-99.8) for Delta, and 87.8% (95% CI: 47.5-97.1) for Omicron. CONCLUSIONS Protection afforded by prior infection in preventing symptomatic reinfection with Alpha, Beta, or Delta is robust, at about 90%. While such protection against reinfection with Omicron is lower, it is still considerable at nearly 60%. Prior-infection protection against hospitalization or death at reinfection appears robust, regardless of variant.”

https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v3

Holm Hansen, C., Blicher Schelde, A., Rask Moustsen-Helm, I., Emborg, H.-D., Grove Krause, T., Mølbak, K., Valentiner-Branth, P., (2021-12-23), Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. Dansk studie  av över 5 000 fall, där dubbel- och trippelinjicerade, löpte upp till 76.5% högre risk att drabbas av Omikron än icke injicerade, vilket tyder på att injektionerna allvarligt skadat immunförsvaret. Att forskarna knappt uppmärksammar detta, kan ha att göra med att medRxiv sponsras av Chan Zuckerberg Initiative, samt att alla forskare som går emot den gällande agendan – att injektionerna är riskfria, löper stor risk att blockeras från sociala medier, sökmotorer och bli utan finansiering.

https://www.medrxiv.org/content/10.1101/2021.11.24.21266735v1?fbclid=IwAR1Ll1KrVFE18pjGUpMYUh6fVZ9jBOkn8wTkqusrd9ru5khpecausQC68yk

Stijn P. Andeweg, Harry Vennema, Irene Veldhuijzen, Naomi Smorenburg, Dennis Schmitz, Florian Zwagemaker, SeqNeth Molecular surveillance group, RIVM COVID-19 Molecular epidemiology group, Arianne B. van Gageldonk-Lafeber, Susan J.M. Hahné, Chantal Reusken, Mirjam J. Knol, Dirk Eggink, (2021-11-24), Increased risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals. ” We find evidence for an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared to the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14-59 days after complete vaccination compared to 60 days and longer. In contrast to vaccine-induced immunity, no increased risk for reinfection with Beta, Gamma or Delta variants relative to Alpha variant was found in individuals with infection-induced immunity.”

https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1

Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Cohen, D., Muhsen, K., Chodick, G., Patalon, T., (2021-08-25), Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity. Individuals who were both previously infected with SARS-CoV-2 and given a single dose of the vaccine gained additional protection against the Delta variant.

https://www.medrxiv.org/content/10.1101/2021.07.31.21261387v1

Riemersma, K. K., Grogan, B. E., Kita-Yarbro, A., Jeppson, G. E., O’Connor, D. H., Friedrich, T. C., Grande, K. M., (2021-07-31), Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant Enligt denna studie, som finansierats av CDC, bär icke injicerade och injicerade på samma mängd virus.

https://www.mdpi.com/1467-3045/44/3/73/htm

Markus Aldén, Francisko Olofsson Falla, Daowei Yang, Mohammad Barghouth, Cheng Luan, Magnus Rasmussen, (2022-02-25), Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. ”Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the BNT162b2 injection. Furthermore, a recent study showed that SARS-CoV-2 RNA can be reverse-transcribed and integrated into the genome of human cells. In this study, we investigated the effect of BNT162b2 on the human liver cell line Huh7 in vitro. Huh7 cells were exposed to BNT162b2, and quantitative PCR was performed on RNA extracted from the cells. We detected high levels of BNT162b2 in Huh7 cells and changes in gene expression of long interspersed nuclear element-1 (LINE-1), which is an endogenous reverse transcriptase. Immunohistochemistry using antibody binding to LINE-1 open reading frame-1 RNA-binding protein (ORFp1) on Huh7 cells treated with BNT162b2 indicated increased nucleus distribution of LINE-1. PCR on genomic DNA of Huh7 cells exposed to BNT162b2 amplified the DNA sequence unique to BNT162b2. Our results indicate a fast up-take of BNT162b2 into human liver cell line Huh7, leading to changes in LINE-1 expression and distribution. We also show that BNT162b2 mRNA is reverse transcribed intracellularly into DNA in as fast as 6 h upon BNT162b2 exposure.”

https://www.journal-of-hepatology.eu/article/S0168-8278(21)02093-6/fulltext#relatedArticles

Gloria Shwe Zin Tun, Dermot Gleeson, Amer Al-Joudeh, Asha Dube, (2021-10-04), Journal of Hepatology, Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed. ”This case illustrates immune-mediated hepatitis secondary to the Moderna vaccine, which on inadvertent re-exposure led to worsening liver injury with deranged synthetic function. This occurred in a well man with no other medical problems. The onset of jaundice associated with the mRNA vaccine was unusually rapid. This was also illustrated in the other cases where symptoms developed over a median of 7 days (range 4-35). Latency is usually longer in other causes of DILI, but can vary depending on mode of injury.”

https://www.journal-of-hepatology.eu/article/S0168-8278(21)00237-3/fulltext

Bril, F., Diffalha, S. A., Dean, M., Fettig, D. M. (2021-07-01), Journal of Hepatology, Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? Fallstudie i Journal of Hepatology från 2021-04-13 av 35-årig kvinna som utvecklat autoimmun hepatit efter sin första injektion.

https://www.janmalmberg.com/sars-cov-2-giftinjektionernas-toxicitet-och-biverkningar-version-10/

Troligen världens mest omfattande länksamling med vetenskapliga studier om SARS-CoV-2-giftinjektionernas toxicitet och biverkningar, som Jan Malmberg sammanställt och utförligt kommenterat och förklarat – inklusive komplicerade begrepp. Totalt finns där 288 vetenskapliga artiklar, som alla säger tvärtemot vad Pfizer, Moderna, media och myndigheter försöker göra gällande.

https://www.cureus.com/articles/93826-correlation-between-mask-compliance-and-covid-19-outcomes-in-europe

Spira, Beny, (2022-04-19), Cureus 14(4), Correlation Between Mask Compliance and COVID-19 Outcomes in Europe. ”Masking was the single most common non-pharmaceutical intervention in the course of the coronavirus disease 2019 (COVID-19) pandemic. Most countries have implemented recommendations or mandates regarding the use of masks in public spaces. The aim of this short study was to analyse the correlation between mask usage against morbidity and mortality rates in the 2020-2021 winter in Europe. Data from 35 European countries on morbidity, mortality, and mask usage during a six-month period were analysed and crossed. Mask usage was more homogeneous in Eastern Europe than in Western European countries. Spearman’s correlation coefficients between mask usage and COVID-19 outcomes were either null or positive, depending on the subgroup of countries and type of outcome (cases or deaths). Positive correlations were stronger in Western than in Eastern European countries. These findings indicate that countries with high levels of mask compliance did not perform better than those with low mask usage.”

https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm

Brown, C. M., Vostok, J., Johnson, H., Burns, M., Gharpure, R., Sami, S., Sabo, R. T., Hall, N., Foreman, A., Schubert, P. L., Gallagher, G. R., Fink, T., Madoff, C. L., Gabriel, S. B., MacInnis, B., Park, D. J., Siddle, K. J., Harik, V., Arvidson, D., Brock-Fisher, T., Dunn, M., Kearns, A., Laney, S., (2021-07-30), Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021.  Deltavarianten har i denna studie som publicerats hos CDC (motsvarande Folkhälsomyndigheten i USA) visat sig kunna föröka sig i princip lika effektivt vid smitta oavsett vaccinationsstatus hos individen, vilket innebär att vaccinimmuniteten sannolikt inte mildrar symtomen vid smitta som för den tidigare alfavarianten. Liknande virusmängder i kroppen innebär även att vaccinerade och ovaccinerade individer är ungefär lika smittsamma.

https://www.bmj.com/content/375/bmj.n2635

Thacker, P. D., (2021-11-02), BMJ, Covid-19: Researcher blows the whistle on data integrity issues in Pfizer’s vaccine trial. BMJ – British Medicine Journal avslöjar att Pfizers ”vaccin” bygger på forskningsfusk. Flera visselblåsare har berättat hur Pfizer på olika sätt har manipulerat resultaten.

https://sites.krieger.jhu.edu/iae/files/2022/01/A-Literature-Review-and-Meta-Analysis-of-the-Effects-of-Lockdowns-on-COVID-19-Mortality.pdf

Jonas Herby, Lars Jonung, and Steve H. Hanke, Johns Hopkins University, (January 2022), A LITERATURE REVIEW AND META-ANALYSIS OF THE EFFECTS OF LOCKDOWNS ON COVID-19 MORTALITY. Enligt denna studie, har restriktionerna i USA och Europa i genomsnitt minskat antalet dödsfall med 0.2%.

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3996320

Jassat, W., Karim, S. A., Mudara, C., Welch, R., Ozougwu, L., Groome, M., Govender, N., von Gottberg, A., Walter, N., Blumberg, L., Cohen, C., (2021-12-29), The Lancet, Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the Omicron-dominant fourth wave. ”Results: There were 41,046, 33,423, and 133,551 SARS-CoV-2 cases in the second, third and fourth waves respectively. About 4.9% of cases were admitted to hospital during the fourth wave compared to 18.9% and 13.7% during the second and third waves (p<0.001). During the fourth wave, 28.8% of admissions were severe disease compared to 60.1% and 66.9% in the second and third waves (p<0.001). Admitted patients in the omicron-dominated fourth wave were 73% less likely to have severe disease than patients admitted during the delta-dominated third wave (adjusted odds ratio [aOR] 0.27, 95% confidence interval [CI] 0.25-0.31).”

https://journals.lww.com/acgcr/fulltext/2022/04000/severe_hepatocellular_liver_injury_after_covid_19.4.aspx

Hoo, Chai-Zhen MD1; Tan, Kar-Choon MD1; Abdullah, Salmi MD2; Sim, Benedict Lim-Heng MD3; Omar, Haniza MD1; Tan, Soek-Siam MD1, (April 2022), ACG Case Reports Journal, Severe Hepatocellular Liver Injury After COVID-19 Vaccination Without Autoimmune Hepatitis Features: A Case Series. Various vaccines were developed and administered to end the pandemic caused by the novel coronavirus diseases 2019 (COVID-19). These vaccines caused rare side effects not known during clinical trials. We report 2 cases of idiosyncratic drug-induced liver injury where the Pfizer BioNTech COVID-19 mRNA vaccine was administered. Both cases showed hepatocellular liver injury with negative autoimmune features on serology and histology and progressed to a protracted course of severe jaundice and pruritus before resolving without any immunosuppressants. We hope to raise awareness of possible rare side effects of the COVID-19 vaccine so that physicians can be vigilant.

https://jamanetwork.com/journals/jama/fullarticle/2788346

Oster, M. E., Shay, D. K., Su, J. R.; et al, (2022-01-25), Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. I den här studien av 1626 fall av myokardit, framgår att risken för myokardit är omkring 133 gånger högre efter injektion med mRNA-preparaten.

https://doctors4covidethics.org/long-term-persistence-of-the-sars-cov-2-spike-protein-evidence-and-implications-2/

Palmer, M., Bhakdi, S., Long-term persistence of the SARS-CoV-2 spike protein: evidence and implications. Abstract: This paper discusses the recent study by Bansal et al. [1] on the detection of spike protein in persons vaccinated with the Pfizer mRNA vaccine. The most significant finding is that spike protein is found on exosomes, that is, cell-derived vesicles, for at least four months after the second injection. This surprisingly long persistence raises the prospect of sustained inflammation within and damage to organs which express the spike protein.  

https://doctors4covidethics.org/immunology-101-why-intramuscular-covid-19-vaccination-must-fail/

Anonymous MD, Palmer, M., Bhakdi, S., Immunology 101: why intramuscular COVID-19 vaccination must fail. Abstract: Many countries are currently experiencing a wave of COVID-19 “breakthrough cases” in spite of high vaccination rates. In this paper, we explain the fundamental reason why such cases had to be expected: the antibodies induced by intramuscular vaccination will only circulate in the bloodstream, but they will not reach the surface of the mucous membranes in the upper airways. We also briefly discuss possible mechanisms of vaccine-induced immunopathology.

https://cormandrostenreview.com/report/

Borger, P., Malhotra, B. R., Yeadon, M., Craig, C., McKernan, K., Steger, K., McSheehy, P., Angelova, L., Franchi, F., Binder, T., Ullrich, H., Ohashi, M., Scoglio, S., van Kleffens, M. D., Gilbert, D., Klement, R., Schruefer, R., Pieksma, B. W., Bonte, J., Dalle Carbonare, B. H., Corbett, K. P.,  Kämmerer, U, (2020-11-27), External peer review of the RTPCR test to detect SARS-CoV-2 reveals 10 major scientific flaws at the molecular and methodological level: consequences for false positive results. Abstract: The debunks of debunks, the “Corman-Drosten Review Report“, avslöjar 10 fatala brister som gör PCR-testerna fullständigt värdelösa.